Yiran Li

Beijing, 100730, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

AARS1 promotes tumor progression and immune evasion via ATF6 lactylation-mediated tryptophan metabolism in hepatocellular carcinoma.

AARS1 promotes tumor progression and immune evasion via ATF6 lactylation-mediated tryptophan metabolism in hepatocellular carcinoma.

Journal: Cell metabolism

Published: August 14, 2025

Spatiotemporal landscape of intrahepatic cholangiocarcinoma liver metastasis at the single-cell level.

Spatiotemporal landscape of intrahepatic cholangiocarcinoma liver metastasis at the single-cell level.

Journal: Hepatology (Baltimore, Md.)

Published: April 29, 2025

Immunosuppression and phenotypic plasticity in an atlas of human hepatocholangiocarcinoma.

Immunosuppression and phenotypic plasticity in an atlas of human hepatocholangiocarcinoma.

Journal: Hepatobiliary surgery and nutrition

Published: August 10, 2023

Genomic characterization and immunotherapy for microsatellite instability-high in cholangiocarcinoma.

Genomic characterization and immunotherapy for microsatellite instability-high in cholangiocarcinoma.

Journal: BMC medicine

Published: July 21, 2023

The efficacy and safety of bevacizumab as a salvage therapy for patients with advanced hepatocellular carcinoma targeting immune tolerance.

The efficacy and safety of bevacizumab as a salvage therapy for patients with advanced hepatocellular carcinoma targeting immune tolerance.

Journal: American journal of cancer research

Published: May 31, 2023

Radiation Therapy With Combination Therapy of Immune Checkpoint Inhibitors and Antiangiogenic Therapy for Hepatocellular Carcinoma.

Radiation Therapy With Combination Therapy of Immune Checkpoint Inhibitors and Antiangiogenic Therapy for Hepatocellular Carcinoma.

Journal: International journal of radiation oncology, biology, physics

Published: January 06, 2023

Development and validation of a selenium metabolism regulators associated prognostic model for hepatocellular carcinoma.

Development and validation of a selenium metabolism regulators associated prognostic model for hepatocellular carcinoma.

Journal: BMC cancer

Published: December 30, 2022

Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients.

Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients.

Journal: Hepatology international

Published: October 11, 2022

Efficacy of immune checkpoint inhibitors plus molecular targeted agents after the progression of lenvatinib for advanced hepatocellular carcinoma.

Efficacy of immune checkpoint inhibitors plus molecular targeted agents after the progression of lenvatinib for advanced hepatocellular carcinoma.

Journal: Frontiers in immunology

Published: September 24, 2022

Identification of an m6A-Related Long Noncoding RNA Risk Model for Predicting Prognosis and Directing Treatments in Patients With Colon Adenocarcinoma.

Identification of an m6A-Related Long Noncoding RNA Risk Model for Predicting Prognosis and Directing Treatments in Patients With Colon Adenocarcinoma.

Journal: Frontiers in cell and developmental biology

Published: April 01, 2022

Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers.

Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers.

Journal: Journal for immunotherapy of cancer

Published: November 04, 2021

Differentially expressed liver exosome-related genes as candidate prognostic biomarkers for hepatocellular carcinoma.

Differentially expressed liver exosome-related genes as candidate prognostic biomarkers for hepatocellular carcinoma.

Journal: Annals of translational medicine

Published: August 21, 2021

Showing 1-12 of 12

Last Updated: 09/26/2026